Outcomes
death
RECURRENCES, RECURRENCE, DISEASE, EVENT, SECONDARY, SECOND PRIMARY MALIGNANCY, EVENTS
The primary endpoint was PFS, defined as time from completion of staging until progression, relapse, or death from any cause. If none of these events had occurred, PFS was censored at the date of last information on the disease status. Predefined secondary endpoints reported herein were overall survival (OS; time from completion of staging until death from any cause or censored at the date of last information on the patient being alive), time to second primary malignancy (SPM; calculated from completion of staging until first SPM diagnosis or censored at the date of last information on disease status, accounting for death as a competing risk), time to in-field and out-field recurrence, with in-field recurrence defined as progression or relapse with at least one localization within the (potential) radiation field, and out-field recurrences as those with at least one localization outside of the (potential) radiation field (calculated from completion of staging until first respective event or censored at the date of last information on disease status, accounting for death or other HL recurrence as competing risks), cardiac function in terms of mean left ventricular ejection fraction (LVEF) after 5 years of follow-up, time to first childbirth (calculated in female patients from last day of study therapy until the day of birth of the first child born after study therapy, or censored at the date of last information on disease status, accounting for death as a competing risk), as well as frequency of children born after therapy and use of cryopreservation.